- Home
- BPMC vs PATH Comparison
BPMC vs PATH Comparison
Compare BPMC & PATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- PATH
- Stock Information
- Founded
- BPMC 2008
- PATH 2005
- Country
- BPMC United States
- PATH United States
- Employees
- BPMC N/A
- PATH N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- PATH Computer Software: Prepackaged Software
- Sector
- BPMC Health Care
- PATH Technology
- Exchange
- BPMC Nasdaq
- PATH Nasdaq
- Market Cap
- BPMC 5.8B
- PATH 6.0B
- IPO Year
- BPMC 2015
- PATH 2021
- Fundamental
- Price
- BPMC $97.17
- PATH $12.49
- Analyst Decision
- BPMC Buy
- PATH Hold
- Analyst Count
- BPMC 21
- PATH 20
- Target Price
- BPMC $124.05
- PATH $12.91
- AVG Volume (30 Days)
- BPMC 973.2K
- PATH 12.4M
- Earning Date
- BPMC 05-01-2025
- PATH 05-29-2025
- Dividend Yield
- BPMC N/A
- PATH N/A
- EPS Growth
- BPMC N/A
- PATH N/A
- EPS
- BPMC N/A
- PATH N/A
- Revenue
- BPMC $562,121,000.00
- PATH $1,429,664,000.00
- Revenue This Year
- BPMC $44.85
- PATH $8.91
- Revenue Next Year
- BPMC $32.06
- PATH $8.99
- P/E Ratio
- BPMC N/A
- PATH N/A
- Revenue Growth
- BPMC 99.19
- PATH 9.30
- 52 Week Low
- BPMC $73.04
- PATH $9.38
- 52 Week High
- BPMC $121.90
- PATH $20.95
- Technical
- Relative Strength Index (RSI)
- BPMC 59.54
- PATH 66.90
- Support Level
- BPMC $87.03
- PATH $11.63
- Resistance Level
- BPMC $104.86
- PATH $12.12
- Average True Range (ATR)
- BPMC 3.86
- PATH 0.35
- MACD
- BPMC 1.24
- PATH 0.15
- Stochastic Oscillator
- BPMC 64.38
- PATH 95.53
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About PATH UiPath Inc.
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.